Multicenter phase 1 trial of oncolytic virus OVV-01 in patients with advanced solid tumors

The oncolytic virus OVV-01 is a genetically engineered vesicular stomatitis virus designed to selectively amplify in tumor cells and express tumor-associated antigen NY-ESO-1. A multicenter, first-in-human, phase 1 study in China evaluated intratumorally administered OVV-01 in patients with advanced solid tumors. There were no dose-limiting toxicities or treatment-related severe adverse events. The objective response rate was 27.3% and the disease control rate was 63.6%. Among patients with soft tissue sarcoma, the ORR was 75%. The median progression-free survival was 17.2 weeks, and the median overall survival was 29.6 weeks.